IP Library Granted Patent US 8,367,101
Granted Patent B2
US 8,367,101 · App. 10/060,849 · Granted Feb 5, 2013

Pharmaceutical formulation

Inventors: Stephen Mark McAllister (Harlow, GB); Ronald K. Raby, Jr. (Collegeville, PA); Adrian Brown (Harlow, GB); Allan J. Clarke (Collegeville, PA); Daniel N. Margetson (Harlow, GB); Wayne Matthews (Harlow, GB)
Assignee: Capsugel Belgium NV
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,101
App. No.
10/060,849
Granted
Feb 5, 2013
Kind
B2
Abstract

The present invention is directed to pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

Claims (34)

1. An extruded, injection molded capsule shell comprising a composition comprising:

a copolymer of methyl acrylate, methyl methacrylate, and methacrylic acid, present in an amount ranging from about 42% to about 72% w/w, with a molar ratio of monomer units of 7:3:1 and a ratio of free carboxyl groups to ester groups of 1:10;

Stearyl alcohol is present in an amount of about 12% w/w;

a surfactant selected from the group consisting of sodium dodecyl sulphate and a block copolymer of ethylene oxide and propylene oxide present in an amount ranging from about 0.1% to about 5% w/w;

a swellable solid present in an amount ranging from about 5% to about 70% w/w selected from the group consisting of, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, and combinations thereof; and

a dissolution modifying excipient present in an amount ranging from about 5% to about 40% w/w selected from the group consisting of sodium starch glycollate, croscarmellose sodium, Lactose, and combinations thereof.

2. The capsule shell according to claim 1 , wherein the composition is selected from the group consisting of:

Copolymer 62.9%, Crosscarmellose sodium 10%, Sodium starch glycollate 10%, Stearyl alcohol 12%, Hydroxypropyl methylcellulose 5%, Sodium dodecyl sulphate 0.1%;

Copolymer 62.75%, Crosscarmellose sodium 10%, Sodium starch glycollate 10%, Stearyl alcohol 12%, Hydroxypropyl methylcellulose 5%, Sodium dodecyl sulphate 0.25%;

Copolymer 52%, Crosscarmellose sodium 15%, Sodium starch glycollate 15%, Stearyl alcohol 12%, Hydroxypropyl methylcellulose 5%, Sodium dodecyl sulphate 1%;

Copolymer 42%, Crosscarmellose sodium 20%, Sodium starch glycollate 20%, Stearyl alcohol 12%, Hydroxypropyl methylcellulose 5%, Sodium dodecyl sulphate 1%;

and

Copolymer 62%, Crosscarmellose sodium 5%, Sodium starch glycollate 5%, Stearyl alcohol 12%, Hydroxypropyl methylcellulose 15%, Sodium dodecyl sulphate 1%.

3. The capsule shell according to claim 1 , wherein the composition is selected from the group consisting of:

Copolymer 68%, Hydroxypropylmethyl cellulose 10%, Lactose (regular) 5%, Sodium dodecyl sulphate 5%, Stearyl alcohol 12%;

Copolymer 72%, Hydroxypropylmethyl cellulose 10%, Lactose (regular) 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%;

Copolymer 71%, Hydroxypropylmethyl cellulose 10%, Lactose (regular) 5%, Sodium dodecyl sulphate 2%, Stearyl alcohol 12%;

Copolymer 62%, Sodium starch glycollate 20%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%;

Copolymer 62.5%, Sodium starch glycollate 20%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 0.5%, Stearyl alcohol 12%;

Copolymer 62%, Croscarmellose sodium 10%, Sodium starch glycollate 10%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%;

Copolymer 67%, Croscarmellose sodium 15%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%;

Copolymer 72%, Croscarmellose sodium 10%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%;

Copolymer 52%, Croscarmellose sodium 15%, Sodium starch glycollate 15%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%;

Copolymer 62.9%, Croscarmellose sodium 10%, Sodium starch glycollate 10%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 0.1%, Stearyl alcohol 12%;

Copolymer 62%, Sodium dodecyl sulphate 1%, Croscarmellose sodium 10%, Sodium starch glycollate 10%, Stearyl alcohol 12%, Hydroxypropylmethyl cellulose 5%;

Copolymer 52%, Sodium dodecyl sulphate 1%, Croscarmellose sodium 15%, Sodium starch glycollate 15%, Stearyl alcohol 12%, Hydroxypropylmethyl cellulose 5%;

Copolymer 62%, Polyoxypropylene-polyoxyethylene block copolymer 1%, Sodium starch glycollate 20%, Stearyl alcohol 12%, Hydroxypropylmethyl cellulose 5%;

and

Copolymer 47%, Stearyl alcohol 12%, Sodium starch glycollate 10%, Hydroxypropylmethyl cellulose 30%, Sodium dodecyl sulphate 1%.

4. An extruded, injection molded capsule shell comprising a composition selected from the group consisting of:

Copolymer 62%, Hydroxypropylmethyl cellulose phthalate 20%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%;

Copolymer 77%, Croscarmellose sodium 5%, Hydroxypropylmethyl cellulose 5%, Sodium dodecyl sulphate 1%, Stearyl alcohol 12%; and

Copolymer 63%, Croscarmellose sodium 10%, Sodium starch glycollate 10%, Hydroxypropylmethyl cellulose 5%, Stearyl alcohol 12%;

wherein the copolymer is a copolymer of methyl acrylate, methyl methacrylate, and methacrylic acid with a molar ratio of monomer units of 7:3:1, and a ratio of free carboxyl groups to esters groups of 1:10.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Jul 10, 2017
From: UBS AG, STAMFORD BRANCH
To: CAPSUGEL BELGIUM BVBA
Reel/Frame 043136/0353 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAME OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 027439 FRAME 0097. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME FROM CAPSUGEL BELGIUM TO CAPSUGEL BELGIUM NV. Recorded Dec 4, 2012
From: CAPSUGEL BELGIUM
To: CAPSUGEL BELGIUM NV
Reel/Frame 029426/0077 →
CHANGE OF NAME Recorded Dec 23, 2011
From: CAPSUGEL BELGIUM BVBA
To: CAPSUGEL BELGIUM
Reel/Frame 027439/0097 →
SECURITY AGREEMENT Recorded Aug 29, 2011
From: CAPSUGEL BELGIUM BVBA
To: UBS AG, STAMFORD BRANCH, AS COLLATERAL AGENT
Reel/Frame 026820/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2011
From: PFIZER INC.
To: CAPSUGEL BELGIUM BVBA
Reel/Frame 026798/0043 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2011
From: SMITHKLINE BEECHAM LIMITED
To: PFIZER INC.
Reel/Frame 025833/0373 →
CHANGE OF NAME Recorded Oct 8, 2010
From: SMITHKLINE BEECHAM P.L.C.
To: SMITHKLINE BEECHAM LIMITED
Reel/Frame 025113/0549 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2002
From: MCALLISTER, STEPHEN MARK; RABY, RONALD K. JR.; BROWN, ADRIAN; CLARKE, ALLAN J.; MARGETSON, DANIEL N.; MATTHEWS, WAYNE
To: SMITHKLINE BEECHAM P.L.C.
Reel/Frame 013013/0313 →
Priority Claims (1)
GB 0102342.3 · Jan 30, 2001 · national
Continuity (1)
Related Publication 20030068369A1 · Apr 10, 2003